Wednesday, June 17, 2026 CCTG would like to welcome Melanie Keats as the new patient representative supporting the Genitourinary Disease Site Committee. Melanie resides in Halifax Nova Scotia and is a a Professor and Associate Research Scholar, Health Populations Research Institute at Dalhousie University as well as a Nova Scotia Health Authority Affiliated Scientist and Co-Director Physical Activity and Cancer (PAC) Lab.“My cumulative experiences have given me a deep appreciation for the realities patients and families face across the cancer trajectory. I am motivated to ensure that clinical trials reflect patient priorities, reduce barriers to participation, and address outcomes that matter most to those living with cancer. I believe that integrating the patient voice strengthens the relevance, accessibility, and impact of cancer research.”Melanie has experienced cancer from multiple perspectives—as a patient, a family member, and a caregiver. Her connection to cancer began early in life when her younger brother was diagnosed with acute myeloblastic leukemia at the age of three and passed away just one month before his fourth birthday; she was only a year and a half at the time. At age 12, Melanie was diagnosed with an aggressive spinal cord astrocytoma. Following surgery and radiation, she required months of physiotherapy to learn to walk again. The treatment weakened my developing spine, ultimately leading to a spinal fusion across six vertebrae. Then at 17 years old, she was diagnosed with bladder cancer, and in 2013, there was a recurrence of her spinal tumor requiring chemotherapy. Most recently, in 2021, she was diagnosed with stage 4A ovarian cancer and has since faced three recurrences.In addition to her own experiences, cancer has also profoundly impacted her family. She lost her grandmother to uterine cancer, her aunt to pancreatic cancer, and most recently, her father to small cell bladder cancer. These experiences have shaped Melanie's perspective and strengthen her commitment to bringing the patient voice to cancer research, grounded in a deep understanding of the challenges faced by patients and their families.“Clinical trials provide opportunities to access new treatments and contribute to advancing cancer care. Participation also allows patients to play an active role in shaping the future of research and improving outcomes for others. From my perspective, patient involvement—both as participants and as partners in research—is essential to developing more patient-centered, effective care.”CCTG is delighted to have Melanie join our Group and look forward to her contributions to the Patient Representative Committee.
